Cargando…

Probiotics for Parkinson’s Disease

Parkinson’s disease (PD) is a complex neurological disorder classically characterized by impairments in motor system function associated with loss of dopaminergic neurons in the substantia nigra. After almost 200 years since the first description of PD by James Parkinson, unraveling the complexity o...

Descripción completa

Detalles Bibliográficos
Autor principal: Gazerani, Parisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747430/
https://www.ncbi.nlm.nih.gov/pubmed/31450864
http://dx.doi.org/10.3390/ijms20174121
_version_ 1783451899137097728
author Gazerani, Parisa
author_facet Gazerani, Parisa
author_sort Gazerani, Parisa
collection PubMed
description Parkinson’s disease (PD) is a complex neurological disorder classically characterized by impairments in motor system function associated with loss of dopaminergic neurons in the substantia nigra. After almost 200 years since the first description of PD by James Parkinson, unraveling the complexity of PD continues to evolve. It is now recognized that an interplay between genetic and environmental factors influences a diverse range of cellular processes, reflecting on other clinical features including non-motor symptoms. This has consequently highlighted the extensive value of early clinical diagnosis to reduce difficulties of later stage management of PD. Advancement in understanding of PD has made remarkable progress in introducing new tools and strategies such as stem cell therapy and deep brain stimulation. A link between alterations in gut microbiota and PD has also opened a new line. Evidence exists of a bidirectional pathway between the gastrointestinal tract and the central nervous system. Probiotics, prebiotics and synbiotics are being examined that might influence gut-brain axis by altering gut microbiota composition, enteric nervous system, and CNS. This review provides status on use of probiotics for PD. Limitations and future directions will also be addressed to promote further research considering use of probiotics for PD.
format Online
Article
Text
id pubmed-6747430
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67474302019-09-27 Probiotics for Parkinson’s Disease Gazerani, Parisa Int J Mol Sci Review Parkinson’s disease (PD) is a complex neurological disorder classically characterized by impairments in motor system function associated with loss of dopaminergic neurons in the substantia nigra. After almost 200 years since the first description of PD by James Parkinson, unraveling the complexity of PD continues to evolve. It is now recognized that an interplay between genetic and environmental factors influences a diverse range of cellular processes, reflecting on other clinical features including non-motor symptoms. This has consequently highlighted the extensive value of early clinical diagnosis to reduce difficulties of later stage management of PD. Advancement in understanding of PD has made remarkable progress in introducing new tools and strategies such as stem cell therapy and deep brain stimulation. A link between alterations in gut microbiota and PD has also opened a new line. Evidence exists of a bidirectional pathway between the gastrointestinal tract and the central nervous system. Probiotics, prebiotics and synbiotics are being examined that might influence gut-brain axis by altering gut microbiota composition, enteric nervous system, and CNS. This review provides status on use of probiotics for PD. Limitations and future directions will also be addressed to promote further research considering use of probiotics for PD. MDPI 2019-08-23 /pmc/articles/PMC6747430/ /pubmed/31450864 http://dx.doi.org/10.3390/ijms20174121 Text en © 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gazerani, Parisa
Probiotics for Parkinson’s Disease
title Probiotics for Parkinson’s Disease
title_full Probiotics for Parkinson’s Disease
title_fullStr Probiotics for Parkinson’s Disease
title_full_unstemmed Probiotics for Parkinson’s Disease
title_short Probiotics for Parkinson’s Disease
title_sort probiotics for parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747430/
https://www.ncbi.nlm.nih.gov/pubmed/31450864
http://dx.doi.org/10.3390/ijms20174121
work_keys_str_mv AT gazeraniparisa probioticsforparkinsonsdisease